Mosaic ImmunoEngineering, Inc. Stock

Mosaic ImmunoEngineering, Inc. is a development-stage biotechnology company focused on advancing cancer therapies for areas of high unmet medical need. The Company has advanced an early-stage product candidate, MIE-101, that is based on a naturally occurring plant virus licensed from Case Western Reserve University (CWRU). Its product candidate, MIE-101, is based on a naturally occurring plant virus known as Cowpea mosaic virus (CPMV). The product is injected directly into a tumor and can act as an in-situ vaccine using markers of the injected tumor as the target which results in the activation of an immune response against the primary tumor and to prime systemic anti-tumor immunity, while reversing immunosuppressive signals in the tumor microenvironment (TME). In addition, the Company is pursuing new product candidates and platforms to expand its pipeline based on an understanding of immunotherapies and its license agreements with University of California San Diego.